Lidds AB Cash Flow Conversion Efficiency

Latest as of September 2025: -0.413x

Lidds AB cash flow conversion efficiency. Based on the latest financial reports, Lidds AB (LIDDS) has a cash flow conversion efficiency ratio of -0.413x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-616.00K ≈ $-66.29K USD) by net assets (Skr1.49 Million ≈ $160.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Lidds AB (2013–2024)

Cash flow conversion efficiency of Lidds AB from 2013 to 2024. This chart illustrates how Lidds AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LIDDS stock price and chart for real-time trading data and today's change.

Lidds AB Cash Flow Conversion Ratio Explained

Lidds AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Lidds AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lidds AB ranked by their cash flow conversion efficiency. Also see how much is Lidds AB worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
SysGroup PLC
LSE:SYS
0.029x
MEDCAW INVESTMENTS LS-01
F:U09
N/A
Wildpack Beverage Inc
V:CANS
0.068x
Israel Opportunity - Energy Resources LP
TA:ISOP-L
-0.055x
Helium One Global Ltd
LSE:HE1
-0.001x
KOYJ Co. Ltd
KQ:121850
-1.361x
BLUERUSH Media Group Corp
V:BTV
-0.015x
Imobiliária Construtora Grão Pará S.A.
LS:GPA
0.000x

Annual Cash Flow Conversion Efficiency for Lidds AB (2013–2024)

The table below shows the annual cash flow conversion efficiency of Lidds AB from 2013 to 2024. Review Lidds AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr6.18 Million
≈ $664.96K
Skr-5.43 Million
≈ $-584.68K
-0.879x +53.39%
2023-12-31 Skr13.90 Million
≈ $1.50 Million
Skr-26.22 Million
≈ $-2.82 Million
-1.886x +18.65%
2022-12-31 Skr15.35 Million
≈ $1.65 Million
Skr-35.59 Million
≈ $-3.83 Million
-2.319x -163.81%
2021-12-31 Skr48.51 Million
≈ $5.22 Million
Skr-42.64 Million
≈ $-4.59 Million
-0.879x -37.23%
2020-12-31 Skr42.81 Million
≈ $4.61 Million
Skr-27.42 Million
≈ $-2.95 Million
-0.641x -470.12%
2019-12-31 Skr152.13 Million
≈ $16.37 Million
Skr-17.09 Million
≈ $-1.84 Million
-0.112x -1131.42%
2018-12-31 Skr158.52 Million
≈ $17.06 Million
Skr-1.45 Million
≈ $-155.64K
-0.009x +89.16%
2017-12-31 Skr127.25 Million
≈ $13.69 Million
Skr-10.71 Million
≈ $-1.15 Million
-0.084x -352.72%
2016-12-31 Skr112.52 Million
≈ $12.11 Million
Skr-2.09 Million
≈ $-225.21K
-0.019x +74.68%
2015-12-31 Skr99.77 Million
≈ $10.74 Million
Skr-7.33 Million
≈ $-788.75K
-0.073x -3.47%
2014-12-31 Skr96.37 Million
≈ $10.37 Million
Skr-6.84 Million
≈ $-736.33K
-0.071x -1.37%
2013-12-31 Skr75.21 Million
≈ $8.09 Million
Skr-5.27 Million
≈ $-566.87K
-0.070x --

About Lidds AB

ST:LIDDS Sweden Biotechnology
Market Cap
$361.27K
Skr3.36 Million SEK
Market Cap Rank
#31194 Global
#730 in Sweden
Share Price
Skr0.02
Change (1 day)
+0.00%
52-Week Range
Skr0.01 - Skr0.06
All Time High
Skr19.64
About

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more